V. Grossmann

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular analyses of 15 , 542 patients with suspected BCR-ABL 1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow by

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

Comprehensive mutational profiling in advanced systemic mastocytosis.

A. Kohlmann, T. Haferlach, W. Hofmann, 2013, Blood.

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

N. Schmitz, N. Klopp, T. Illig, 2013, Leukemia.

A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration.

Peter K. Joshi, Lorna M. Lopez, Min A. Jhun, 2016, Human molecular genetics.

Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the VTEval Project

U. Walter, P. Wild, K. Lackner, 2015, BMJ Open.

Distribution, genetic and cardiovascular determinants of FVIII:c - Data from the population-based Gutenberg Health Study.

S. Blankenberg, M. Beutel, N. Pfeiffer, 2015, International journal of cardiology.

The role of the RAS pathway in iAMP21-ALL

A. Kohlmann, T. Haferlach, B. Keavney, 2016, Leukemia.

Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Blood.

Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Genes, chromosomes & cancer.

A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia

F. Bosch, P. Abrisqueta, I. Marugán, 2015, PloS one.

Ultra-Deep Next-Generation Sequencing Detects RUNX1 Mutations with Unprecedented Sensitivity and Allows to Monitor Minimal Residual Disease In 116 Samples From MDS and AML Patients

A. Kohlmann, T. Haferlach, S. Schnittger, 2010 .

ASXL1 exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with An Extremely Poor Outcome

A. Kohlmann, T. Haferlach, S. Schnittger, 2011 .

R453Plus1Toolbox: an R/Bioconductor package for analyzing Roche 454 Sequencing data

Martin Dugas, Hans-Ulrich Klein, Christoph Bartenhagen, 2011, Bioinform..

PLATELETS AND THROMBOPOIESIS Sex-speci ﬁ c differences in genetic and nongenetic determinants of mean platelet volume: results from the Gutenberg Health Study

S. Blankenberg, M. Beutel, T. Zeller, 2015 .

Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Leukemia.

SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology.

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2011, The Journal of molecular diagnostics : JMD.

The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, Genes, chromosomes & cancer.

Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact

T. Haferlach, S. Schnittger, W. Kern, 2014, British journal of haematology.

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 75% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2 , RUNX1 , CBL , and RAS .

A. Kohlmann, T. Haferlach, S. Schnittger, 2009 .